FDA Requiring Lower Doses for Sleep Drugs

Wednesday, 27 Feb 2013 06:20 PM

By Nick Tate

Share:
More . . .
A    A   |
   Email Us   |
   Print   |
The U.S. Food and Drug Administration is requiring manufacturers to lower the recommended dose for sleep drugs approved for bedtime use that contain zolpidem, the most widely used active ingredient in prescription sleep medications.
 
The ingredient — contained in the brand name drugs Ambien, Ambien CR, Edluar, Zolpimist, and in generic sleeping pills — may remain high enough in the blood of people who take them to make them less alert in the morning and even impair certain activities that require mental acuity.
 
The FDA said risks are highest for people who take products containing extended-release zolpidem (Ambien CR and generics). Women are especially vulnerable because zolpidem is cleared from the body more slowly in women than in men.
 
The recommended doses of Intermezzo, a lower dose zolpidem product approved for middle-of-the-night awakenings, are not changing.

The FDA also issued the following recommendations for people who take sleeping pills:
  • Be aware that sleep drugs can cause impaired alertness the next morning, even if you feel fully awake.
  • Talk to your healthcare professional about how to take the lowest effective dose of sleep drugs.
  • Don’t assume that over-the-counter sleep medicines are necessarily safer alternatives to prescription drugs.

© 2013 NewsmaxHealth. All rights reserved.

Share:
More . . .
   Email Us   |
   Print   |

Join the Newsmax community.
Register to share your comments with the community. Already a member? Login
Note: Comments from readers do not necessarily reflect the viewpoint of Newsmax Media. While we attempt to review comments, if you see an inappropriate comment you can block it by rolling over the comment, clicking the down arrow and selecting "Flag As Inappropriate."
blog comments powered by Disqus
 
Email:
Country
Zip Code:
 
Find Your Condition
Follow Newsmax

You May Also Like

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved